Though the market for this product in India is pegged at Rs two crore, analysts estimate its value in the US markets to be around $25 million.
The company along with Madras University has jointly developed Virohep, a product showing promising results in treatment and cure of viral hepatitis B. It also has strong evidence to support that the product is also effective in hepatitis C and HIV, Shreya Life Science director Ajit Bhaskar said.
The product contains active ingredient hepavirin derived from a plant -- phyllanthus amarus. Shreya has an exclusive arrangement with Madras University to market the product worldwide.
The company is also on the lookout of a strategic partner in US. It has forayed into biotech with the setting up of a new company -- Shreya Biotech. This company has acquired a 10 acre site at the biotech park at Hingewadi in Pune and is expected to commence operations in January 2004. Shreya Biotech is a joint venture between Shreya group, Scitech, US and SciGen Inc, Singapore.